These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2392 related items for PubMed ID: 28154019

  • 21. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

  • 22. Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging?
    Zhou Y, Li L, Wang H, Huang HX, Cao D, Ke NW, Su MG, Tian R.
    Clin Nucl Med; 2024 Jun 01; 49(6):516-520. PubMed ID: 38637950
    [Abstract] [Full Text] [Related]

  • 23. The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.
    Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z.
    Mol Imaging Biol; 2019 Oct 01; 21(5):984-990. PubMed ID: 30796708
    [Abstract] [Full Text] [Related]

  • 24. Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma.
    Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J, Zhao L, Sun L, Wu H, Chen X, Lin Q, Chen H.
    Eur J Nucl Med Mol Imaging; 2022 Mar 01; 49(4):1360-1373. PubMed ID: 34665275
    [Abstract] [Full Text] [Related]

  • 25. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct 01; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
    You H, Kandathil A, Beg M, De Blanche L, Kazmi S, Subramaniam RM.
    Nucl Med Commun; 2020 Oct 01; 41(10):1060-1065. PubMed ID: 32732600
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors.
    Komek H, Can C, Urakçi Z, Kepenek F.
    Nucl Med Commun; 2019 May 01; 40(5):517-524. PubMed ID: 30694875
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
    Chang L, Bi X, Li S, Tong Q, Gu Y, He Z, Li Y, Chen Q, Cui J, Yu H, He Q, Liu M.
    Front Endocrinol (Lausanne); 2023 May 01; 14():1163176. PubMed ID: 37455905
    [Abstract] [Full Text] [Related]

  • 33. Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (18F-fluorodeoxyglucose and 68Ga-DOTATATE) correlates and their treatment implications.
    Loharkar S, Basu S.
    World J Nucl Med; 2021 May 01; 20(1):125-128. PubMed ID: 33850504
    [Abstract] [Full Text] [Related]

  • 34. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan 01; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A, Stegger L, Wenning C, Noto B, Burg MC, Konnert JR, Allkemper T, Heindel W, Riemann B, Schäfers M, Weckesser M.
    Eur J Nucl Med Mol Imaging; 2016 Sep 01; 43(10):1765-72. PubMed ID: 27059853
    [Abstract] [Full Text] [Related]

  • 37. Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study.
    Liu Q, Zang J, Yang Y, Ling Q, Wu H, Wang P, Lu L, Zhu Z.
    Eur J Nucl Med Mol Imaging; 2021 Dec 01; 48(13):4386-4395. PubMed ID: 34146130
    [Abstract] [Full Text] [Related]

  • 38. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP.
    J Nucl Med; 2019 Mar 01; 60(3):377-385. PubMed ID: 30115686
    [Abstract] [Full Text] [Related]

  • 39. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
    Hell J Nucl Med; 2015 Mar 01; 18(1):19-24. PubMed ID: 25679074
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 120.